Current status of autologous stem cell transplantation for multiple myeloma

More than 30 years after its introduction, autologous stem cell transplantation (ASCT) remains the standard of care for young patients with newly diagnosed multiple myeloma. Not only did the arrival of novel agents such as immunomodulatory drugs (IMiDs), proteasome inhibitors (PI) and monoclonal ant...

Descripción completa

Detalles Bibliográficos
Autores principales: Al Hamed, Rama, Bazarbachi, Abdul Hamid, Malard, Florent, Harousseau, Jean-Luc, Mohty, Mohamad
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2019
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6453900/
https://www.ncbi.nlm.nih.gov/pubmed/30962422
http://dx.doi.org/10.1038/s41408-019-0205-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6453900/
https://www.ncbi.nlm.nih.gov/pubmed/30962422
http://dx.doi.org/10.1038/s41408-019-0205-9

Ejemplares similares